Claim: In phase 2 clinical trials, at 48 weeks, people on the top dose of 12 milligrams of Retatrutide lost an average of 24% of their body weight.
Verdict: Correct (95% confidence)
Explanation: According to PubMed, a Tier 1 source, phase 2 clinical trials of Retatrutide showed that participants on a 12 mg dose lost an average of 24% of their body weight over 48 weeks. ScienceDirect, a Tier 6 source, corroborates this finding, stating that the weight reduction was up to 24.2% at 48 weeks. Additional support comes from NEJM, a Tier 8 source, which confirms the same weight loss percentage in the trial. The consistent findings across multiple credible sources confirm the claim's accuracy.